key: cord-0746995-m81idzob
authors: Lu, Xiuyuan; Hosono, Yuki; Ishizuka, Shigenari; Nagae, Masamichi; Ishikawa, Eri; Motooka, Daisuke; Ozaki, Yuki; Sax, Nicolas; Shinnakasu, Ryo; Inoue, Takeshi; Onodera, Taishi; Matsumura, Takayuki; Shinkai, Masaharu; Sato, Takashi; Nakamura, Shota; Mori, Shunsuke; Kanda, Teru; Nakayama, Emi E.; Shioda, Tatsuo; Kurosaki, Tomohiro; Arase, Hisashi; Yamashita, Kazuo; Takahashi, Yoshimasa; Yamasaki, Sho
title: Identification, crystallization and epitope determination of public TCR shared and expanded in COVID-19 patients
date: 2021-03-23
journal: bioRxiv
DOI: 10.1101/2021.03.23.436573
sha: fc4f560a35321e5138d41fb94e730cb3b86327a2
doc_id: 746995
cord_uid: m81idzob

T cells play pivotal roles in protective immunity against SARS-CoV-2 infection. Follicular helper T (Tfh) cells mediate the production of antigen-specific antibodies; however, T cell receptor (TCR) clonotypes used by SARS-CoV-2-specific Tfh cells have not been well characterized. Here, we first identified and crystallized public TCR of Tfh clonotypes that are shared and expanded in unhospitalized COVID-19-recovered patients. These clonotypes preferentially recognized SARS-CoV-2 spike (S) protein epitopes which are conserved among emerging SARS-CoV-2 variants. These clonotypes did not react with S proteins derived from common cold human coronaviruses, but cross-reacted with symbiotic bacteria, which might confer the publicity. Among SARS-CoV-2 S epitopes, S864-882, presented by frequent HLA-DR alleles, could activate multiple public Tfh clonotypes in COVID-19-recovered patients. Furthermore, S864-882-loaded HLA tetramer preferentially bound to CD4+ T cells expressing CXCR5. In this study, we identified and crystallized public TCR for SARS-CoV-2 that may contribute to the prevention of COVID-19 aggravation.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a worldwide pandemic with emerging mutations and continuous development of robust vaccine is imperative. Neutralizing antibodies are a major component of a protective immunity against SARS- CoV-2 (Tay et al., 2020) , and thus information about virus-specific CD4 + T cells that help B cells to produce antigen-specific antibodies is needed. Among CD4 + T cells, follicular helper T (Tfh) cells mediate germinal center B cells maturation and production of high affinity antibodies (Crotty, 2019). Some deceased COVID-19 patients exhibited incomplete Tfh cell development (Kaneko et al., 2020) , suggesting that efficient Tfh induction is a key to protective immunity against SARS-CoV-2 (Gong et al., 2020; Zhang et al., 2020) . Furthermore, the characterization of SARS-CoV-2-specific Tfh cells bearing common TCR shared between different individuals will help us to understand and predict host responses during infection.

However, such public Tfh clonotypes specific for SARS-CoV-2 have not yet been reported.

Given that V(D)J recombination is a random process, presence of shared TCR between individuals is generally thought to be a rare event (Soto et al., 2020; Venturi et al., 2008) . Common antigens are one of the reasons that maintain such public clonotypes in the periphery (Li et al., 2012; Venturi et al., 2008) . Recently, some T cells recognizing common cold human coronaviruses (HCoVs) are reported to cross-react with SARS-CoV-2 (Braun et al., 2020; Mateus et al., 2020; Woldemeskel et al., 2020) , whereas SARS-CoV-2-specific T cells that do not react with HCoVs are frequently detected (Bacher et al., 2020; Mateus et al., 2020) . Currently, other cross-reactive antigens recognized by SARS-CoV-2-specific T cells have not been well examined.

In this study, using single cell-based paired TCR analysis together with a rapid TCR reconstitution and epitope determination platform, we identified 1) public TCRs of Tfh cells specific for SARS-CoV-2 expanded in convalescent patients, 2) their epitope peptides and restricting HLA alleles, and 3) their cross-reactive proteins from symbiotic bacteria.

We first analyzed SARS-CoV-2-specific T cell subsets and their clonotypes using a single cell-based RNA sequencing platform. Peripheral blood mononuclear cells (PBMCs) isolated from healthy donors and convalescent COVID-19 patients (Table S1 and S2) were stimulated with antigens derived from SARS-CoV-2, including inactivated virus, recombinant S protein, overlapped peptide pools derived from S protein (S peptide pool) or membrane (M) and nucleocapsid (N) proteins (MN peptide pool). Activation marker-positive T cells were sorted and analyzed for their T cell receptor (TCR) sequences together with RNA expression by single cell TCR-seq and RNA-seq analyses ( Figure S1 ). UMAP embedding and clustering allowed identification of a cluster (#8) consisting of CD4 + cells expressing Tfh-related genes, such as CD200, PDCD1, ICOS, CXCL13, CD40LG and CXCR5, suggesting that cluster #8 includes circulating Tfh cells (Crotty, 2019; Schmitt et al., 2014) (Figure 1A and 1B) . Within this Tfh cluster, we could identify 1735 TCRs (Table S3) . Furthermore, in the S-reactive Tfh cluster, we detected clones bearing TCRαβ pairs shared between different patients, Ts-017 and Ts-018, who had antibodies against receptor binding domain (RBD) of S protein and neutralizing antibodies (Table S1 ). Considering the cell number of single cell TCR-seq, these are likely to be frequent public TCRs and we designated them as TCR-017 and TCR-018, respectively. TCR-017 and -018 had the same Vα, Jα, Vβ and Jβ usages and their complementarity-determining region 3 (CDR3) sequences were identical except for one amino acid in CDR3β ( Figure 1C and 1D). TCR-018 was detected in patient Ts-018 as three different barcoded clones within S protein/peptides-reactive Tfh cluster (Table S3 ).

To examine the antigen specificity of TCR-017 and -018, the respective TCRα and β chains were reconstituted in a TCR-deficient T cell hybridoma bearing an NFAT-GFP reporter ( Figure 1E ). TCR-transfectants were stimulated with SARS-CoV-2 antigens in the presence of transformed B cells derived from the same patients as autologous antigen-presenting cells (APCs). Cells expressing TCR-017 and -018 responded to recombinant S protein and S peptide pool, but not to MN peptide pool ( Figure 2A ), which is consistent with the initial antigen specificity revealed in single cell analysis (Table S3 ). Among two halves of pooled S peptides, #1 (S 1-643 ) and #2 (S 633-1273 ), only #2 pool reacted with both TCRs ( Figure 2B ). However, another SARS-CoV-2 S peptide pool (S 304-338, 421-475, 492-519, 683-707, 741-770, 785-802, 885-1273 ) did not activate either clone ( Figure S2A and Figure 2B ). The above results suggest that the antigen epitope(s) of TCR-017 and -018 is located in regions 633-682, 708-740, 771-784 or 803-884 of S protein ( Figure S2A ).

To further reduce the number of epitope candidates, we next determined the HLA alleles that restrict TCR-017 and -018. Heterologous APCs from patient Ts-017 could activate TCR-018, and vice versa, demonstrating that these APCs are interchangeable ( Figure S2B ). Thus, the shared HLA class II alleles, DRA-DRB1*15:01, DQA1*01:02-DQB1*06:02 or DPA1*02:02-DPB1*05:01 (shown in red in Table S2 ), are likely to restrict this recognition. Since DRB1*15:01 and DQB1*06:02 are genetically linked and would not be segregated from each other (Begovich et al., 1992) , these HLA alleles were separately transfected into HEK293T cells to examine their ability to present S peptides to TCR-017 and -018. Only cells transfected with DRA and DRB1*15:01 could activate both clones in the presence of S peptide pool #2 ( Figure 2C ), suggesting that the reactivity is determined by DRB1*15:01, as DRA is monomorphic. Two epitopes, S 828-846 and S 864-882 , were predicted as strong binders to DRA-DRB1*15:01 using NetMHC server software (Reynisson et al., 2020) within the candidate regions described above ( Figure S2A ).

Among them, S 864-882 was identified as the epitope for both clones ( Figure 2D ). Judging from their dose-response curves, relative affinities of TCR-017 and -018 to this peptide appeared comparable ( Figure 2E ). Furthermore, antigenic activities of serial overlapping peptides indicated that S 870-878 is a minimum epitope recognized by these TCRs ( Figure 2F ). Taken together, both TCR-017 and -018 recognized the same epitope on the same HLA with similar affinities, indicating that TCR-017 and -018 are considered as one clonotype, clonotype-017/018, shared by different donors.

Among other HLAs predicted to strongly bind S 864-882 (Reynisson et al., 2020) , we found that DRB1*15:02/*15:03/*15:04, but not DRB1*16:02 and DQA1*01:01-DQB1*05:01, were restricting HLA that present this epitope to activate clonotype-017/018 ( Figure S2C and S2D).

Consistent with the high frequency of DRB1*15:02 (10.6%) and *15:01 (7.7%) in the Japanese population (http:/hla.or.jp), bulk TCR sequencing of pre-pandemic Japanese donors revealed that TCRα and β chains of clonotype-017/018 were broadly shared by 14.8% and 33.3%, respectively, of the population ( Figure 2G ).

As DRB1*15 are not minor alleles worldwide (Gonzalez-Galarza et al., 2020) , we analyzed TCR databases of healthy and convalescent COVID-19 cohorts containing donors of various ethnicities (Emerson et al., 2017; Nolan et al., 2020) and found that 17% and 24%, respectively, possessed TCRβ-017/018 ( Figure 2H ). These results suggest that clonotype-017/018 is a public clonotype in multiple ethnicities.

We therefore examined whether any of 1735 paired TCRs detected in our sample pool are found in these cohorts. 855 out of 1735 were revealed to be public Tfh TCRs (Table S3 ), indicating that TCR-017/018 is not an exceptional clonotype. Among them, we identified 10 Tfh clonotypes which were significantly expanded in recovered COVID-19 patients compared with the healthy cohort ( Figure 3A , column J, asterisks).

Of note, a half of such clonotypes were indeed detected in multiple patients in our sample pool by single cell TCR sequencing ( Figure 3A , column A, #), and TCR-017/018 was the fifth most significantly expanded clonotype ( Figure 3A , column A and J).

To efficiently determine the epitopes of these clonotypes, we established a rapid epitope-determination platform ( Figure S3A ) and validated it using TCR-017/018 ( Figure 3B , clonotype 5). By using this platform, we further determined the epitopes for other COVID-19-expanded Tfh clonotypes ( Figure 3B ). Restricting HLAs of these epitopes were determined using overlapped HLA alleles in the combination of transformed B cells from different individuals, and individual HLA transfectants (Table   S2 and Figure S3B -S3F). These results indicate that the public Tfh clonotypes which significantly expanded in unhospitalized, recovered patients preferentially recognized S epitopes ( Figure 3A and 3B). All identified epitopes were located in two major hotspots within the conserved trimer-forming interface of S protein with low mutation rates ( Figure 3C ) (Elbe and Buckland-Merrett, 2017; Singer et al., 2020) . In addition, the donors of these clonotypes had anti-RBD and neutralizing antibodies (Table S1 ). These results suggest that public Tfh clonotypes specific for conserved S epitopes have expanded during SARS-CoV-2 infection and presumably contributed to the recovery from mild symptoms (Emerson et al., 2017; Nolan et al., 2020) .

We demonstrated that TCRβ-017/018 is highly public and expanded in the recovered patients ( Figure 3A ). Since the nonidentical amino acid, Q94 and P94 of TCRβ-017 and -018, respectively, have distinct characteristics, we suspected that any amino acid at this position allows epitope recognition. Indeed, any of 17 substitutions, except for D94, retained the reactivity to S 864-882 epitope on DRA-DRB1*15:01 ( Figure   4A ). Indeed, crystallographic analysis of TCR-017 complex demonstrated that the residue at position 94 in CDR3β is located away from CDR3α ( Figure 4B and 4C) and thus unlikely to contact with peptide-MHC. In addition, C90, A91, S92 and S93 were more distant from CDR3α ( Figure 4C ), suggesting that this TCRβ may mainly utilize a C-terminal half of CDR3β for recognition and allow diverse TCR sequence variants or even other TRBVs.

This promiscuity within CDR3β sequence should expand the pool of this public clonotype, which gives us a more precise expansion rate in recovered patients.

Indeed, the expansion of the extended clonotype in the COVID-19-recovered cohort became much more significant (p = 1.6 × 10 −6 ) ( Figure 4D ) than the value shown in Figure 3A (p = 0.003). Furthermore, its occurrence became more than half in all three cohorts ( Figure 4E ), suggesting that the extended clonotype 5 is broadly shared among a large population.

We next asked how these clonotypes, particularly clonotype 5, acquired publicity. Cross-reactivity with the common cold coronaviruses is one of the possible mechanisms (Braun et al., 2020; Grifoni et al., 2020; Mateus et al., 2020) . However, none of the clonotypes identified in this study including TCR-017/018 reacted with S proteins derived from common cold human coronavirus (HCoV) strains ( Figure 3B and Figure S3A , S4A and S4B). Indeed, these HCoVs do not have identical sequences to SARS-CoV-2 epitopes determined in Figure 3B ( Figure 5A ). Furthermore, peptides in the corresponding regions derived from these coronaviruses including severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome-related coronavirus (MERS-CoV) were not recognized by TCR-017/018 ( Figure S4C and S4D) . Thus, these clonotypes are unlikely to acquire publicity by cross-reacting with reported human coronaviruses present before the outbreak of COVID-19. This raises a hypothesis that some other common antigen(s) may confer publicity on these clonotypes. In line with this, BLAST homology search of S 870-878 core epitope revealed that oral commensal bacteria, Selenomonas noxia, express a protein, multidrug and toxic compound extrusion (MATE) family efflux transporter, that includes the same epitope with S 870-879 , IAQYTSALLA ( Figure 5A ). Indeed, the synthetic peptides (MATE 241-260 and 242-256 ) were recognized by both TCR-017 and -018 on DRB1*15:01 ( Figure 5B ). In addition, if any amino acids within this S epitope are replaceable, further cross-reactive proteins might be found. To identify such acceptable substitutions, we performed Alanine/Glycine scanning of S 870-878 peptides and found that seven single substitutions, except for positions Q872 and T874, retained antigenicity of the epitope ( Figure 5C ). Among these mutated epitopes, the sequence of L877A (IAQYTSAAL) was found in a protein expressed by various bacteria, histidine ammonia-lyase (HAL, EC 4.3.1.3) (Table S4 and Figure 5A ).

Other 9 public Tfh clonotypes significantly expanded in patients were also unresponsive to HCoVs ( Figure 3B ). Instead, homology searches for the epitopes of these clonotypes ( Figure 3B ) revealed that S 753-759 , an epitope of clonotype 2, was contained in proteins of various organisms including symbiotic bacteria, such as Bacteroidales bacteria and Klebsiella pneumoniae (Atarashi et al., 2017; Sefik et al., 2015) (Table S5 and Figure 5A ). Indeed, these bacterial peptides, such as TonB-dependent receptor (TBDR) 169-183 and yersiniabactin ABC transporter ATP-binding/permease protein (YbtP) 270-284 , respectively, could activate T cells reconstituted with clonotype 2 TCR ( Figure 5D ). Furthermore, E. coli transformed with the expression vectors for these proteins could activate public clonotypes in the presence of HLA-matched dendritic cells ( Figure 5E ), confirming that cross-reactive antigenic epitopes are processed and presented by APCs. These observations suggest that continuous priming via symbiotic bacteria might explain the high frequency of the public clonotypes worldwide ( Figure 4E ). Further cohort studies will clarify the etiological relationships between these bacteria and resistance against SARS-CoV-2 infection.

Among 1735 TCRs derived from Tfh cluster (Table S3) , we identified another clonotype from patient Ts-017 that recognizes the exact same epitope, S 864-882 , restricted by DRB1*15:01, despite it had distinct V/J usages and CDR3 sequences/lengths from TCR-017/018 ( Figure S5 ). This clonotype was also public as it was detected in cohorts (Table S3 , Seurat barcode, DB2_CAAGAAAGTGCGGTAA). Thus, this epitope, S 864-882 , could activate multiple public Tfh clonotypes even in the same patient.

To further examine the ability of this epitope to activate multiple Tfh clonotypes, PBMCs from additional convalescent/healthy donors possessing DRB1*15:01/*15:02 were stimulated with S 864-882 in vitro. After epitope-induced expansion for 10 days, CD4 + T cells were subjected to single cell-TCR-and RNA-seq to determine the antigen-responsive clonotypes ( Figure 6A and Table S6 ). As a result, we newly identified 104 public Tfh clonotypes that responded to S 864-882 after filtering by two criteria; 1) expanded during stimulation based on single cell sequencing (> 0.1% of total CD4 + T cells) and 2) detected in cohort databases ( To examine the presence of these S 864-882 -reactive clones in the periphery of donors before in vitro expansion, we assembled all expanded TCRαβ pairs with bulk TCR sequences of unstimulated peripheral T cells ( Figure 6A , day 0). Approximately 20% of S 864-882 -reactive TCRα and β chains detected at day 10 (Table S6) were present in the 'day 0' bulk TCR sequences from all recovered patients possessing anti-S protein antibodies (Table S1 ), whereas none of such S 864-882 -reactive TCRs were detectable in healthy control before stimulation ( Figure 6B ). This data provides an implication that some S 864-882 -reactive Tfh clones have been expanded in recovered patients during SARS-CoV-2 infection and maintained as a memory pool after infection.

To directly detect S 864-882 -reacting T cells in PBMCs, we generated DRA-DRB1*15:01 tetramer loaded with this epitope, which was confirmed to bind to recombinant soluble TCR-017αβ in vitro ( Figure S6A and S6B). In healthy donors possessing DRB1*15:01, tetramer-positive CD4 + T cells (approximately 0.005% of T cells) expressed higher CXCR5 than tetramer-negative CD4 + cells ( Figure 6C ). After in vitro activation by S 864-882 peptide, the percentages of tetramer-positive CD4 + T cells were markedly increased and CXCR5 + population was further accumulated ( Figure 6C ), suggesting that S 864-882 peptide is capable of generating activated CD4 + T cells with Tfh profiles.

Recently, public TCR for SARS-CoV-2 has been extensively studied (Shomuradova et al., 2020) . In this study, we report the first identification and structural determination of SARS-CoV-2-specific public TCR of CD4 + T cells. Furthermore, we identified multiple public Tfh clonotypes that were significantly expanded in COVID-19-recovered patients by preferentially recognizing conserved S epitopes.

These observations suggest that the individuals possessing such public Tfh clonotypes could efficiently respond to S protein and produce antibodies against the cognate antigen, which may contribute to the prevention of disease aggravation and subsequent recovery (Table S1 ) (Emerson et al., 2017; Nolan et al., 2020) . As these public clonotypes were widely detected in multiple ethnicities, the precise monitoring of the frequencies of public Tfh clonotypes using tetramer or clonotypic mAb could provide a novel option for prognosis prediction. Furthermore, such common S epitopes are candidates for next-generation vaccine that promote Tfh responses against SARS-CoV-2 and prevent aggravation.

The current study still has several limitations. 1) We analyzed only PBMCs.

Although circulating Tfh cells in the periphery can reflect Tfh cells in germinal center (Crotty, 2019; Heit et al., 2017; Hill et al., 2019; Locci et al., 2013; Schmitt et al., 2014) , the analysis of tissue resident Tfh cells of biopsy samples is ideal to fully characterize Tfh clonotype. 2) Although the present study suggests that these Tfh clonotypes contribute to amelioration of COVID-19 in patients recovered from mild symptoms, additional studies on patients with severe symptoms are helpful for further aspects. Notwithstanding, the current study proposes that combination of single cell paired TCR sequencing and public database is a potent tool to identify public clonotypes which actually responded to SARS-CoV-2 in patients. The rapid reconstitution and determination platform enables us to identify epitopes and responsible HLA simultaneously. As the identified T cell epitopes are conserved among See also Figure S1 and Table S1-S3. (B-D) Cells expressing TCR-017 or TCR-018 were stimulated with 0.3 µg/ml S peptide pool #1, #2 or Selected S pool (S 304-338, 421-475, 492-519, 683-707, 741-770, 785-802, 885-1273 See also Figure S2 and Table S3 . Clonotypes were listed following the order of significance of TCRβ expansion. *, Clonotypes expanded significantly in recovered patients (p < 0.05) (column J).

(B) TCR pair of each clonotype listed in (A) was reconstituted in reporter cells and tested as described in Figure Restricting HLAs were determined as described in Figure S3B -F, Table S2 and Methods. Clonotypes 1 and 6 did not respond to S peptide pools. TCRαβ of clonotype 8 was not expressed on the cell surface.

(C) Locations of epitopes described in (B) are highlighted in red in 3D structure of SARS-CoV-2 S protein (PDB code: 6XR8). Frequencies of mutation (mutation rate) defined relative to Wuhan-Hu-1 were calculated based on the data from CoV-GLUE that enabled by data from GISAID.

See also Figure S3 and Table S3 . See also Figure S4 and Table S4 and S5. peptide for 10 days before CD4 + T cells were sorted and analyzed by single cell TCR-and RNA-seq as well as bulk TCR-seq.

(B) Numbers of TCRα and β of expanded clonotypes (proportion > 0.1% in single cell TCR-seq) detected in bulk TCR-seq described in Table S6 are shown.

(C) PBMCs from healthy donors possessing DRB1*15:01 were stained with S 867-881 -loaded DRA-DRB1*15:01 tetramer along with anti-CD4 and anti-CXCR5

antibodies before or after S 864-882 stimulation followed by flowcytometric analysis.

Percentages of CXCR5 + cells within tetramer-positive (Tet + ) and -negative (Tet -) CD4 + cells are shown.

All data are representative of at least two independent experiments.

See also Figure S5 and S6 and Table S6 .

The Institutional Review Boards of Osaka University (approval number 898-4) and

National Written informed consent was obtained from all participants or designated healthcare surrogates if participants were unable to provide informed consent. Study enrollment criteria included subjects over 20 years old, regardless of disease severity and genders (Table S1 ). Prior to enrollment in this study, all COVID-19 donors were confirmed to be positive for SARS-CoV-2 by PCR using nasopharyngeal swab specimens. Blood from convalescent COVID-19 donors and healthy donors was obtained at Tokyo Shinagawa Hospital and Osaka University. Samples were de-identified prior to analyses.

For PBMC preparation, whole blood was collected in heparin-coated tube and centrifuged to separate the cellular fraction and plasma, followed by density-gradient sedimentation. For neutralizing antibody assay, plasma samples from patients were heat-inactivated for 30 min at 56°C. Plasma diluted at 1:5 followed by two-fold serial dilutions was incubated with equal volume of solution containing 100 TCID 50 of SARS-CoV-2 for 1 hour at 37°C and added to VeroE6/TMPRSS2 cells. After incubation for 5 days, the highest plasma dilution that protected 100% of cells from cytopathic effect was taken as the neutralization titer. Disease severity was defined as mild, moderate I, moderate II or severe in accordance with the Japanese COVID-19 clinical practice guideline ver. 2.2 (https://www.mhlw.go.jp/content/000650160.pdf).

For the preparation of inactivated SARS-CoV-2, SARS-CoV-2 (KNG19-020) was kindly supplied by Dr. Tomohiko Takasaki 

Inactivated virus was used at 2.9 × 10 6 viral particles/ml (approximately 1 µg S protein/ml) for stimulation. For the preparation of recombinant SARS-CoV-2 S protein, the ectodomain of S protein was cloned into a mammalian expression vector pCMV, with a foldon sequence followed by 9 × His-tag and Strep-tag at the C-terminus.

Polybasic cleavage site (RRAR) of S protein was replaced by a single alanine, and K986P and V987P mutations were introduced to stabilize the conformation as previously described (Amanat et al., 2020) . 

Cryopreserved PBMCs were thawed and washed with RPMI 1640 medium (Sigma)

supplemented with 5% human AB serum (GeminiBio), Penicillin (Sigma), streptomycin (MP Biomedicals) and 2-mercaptoethanol (Nacalai Tesque). 5 × 10 5 PBMCs were stimulated in the same medium with inactivated SARS-CoV-2, 1 or 10 µg/ml of recombinant S protein, 1 µg/ml of S peptide pool or 1 µg/ml of M + N (MN) peptide pool for 20 hours, followed by staining with anti-human CD3, CD69, CD137, CD154

and TotalSeq-C Hashtags antibodies. CD69 + , CD137 + or CD154 + cells within CD3 + -gated population were sorted by cell sorter SH800S (SONY) and used for single cell TCR and RNA sequencing analyses. For epitope-specific clonal expansion, 1-5 × 10 5 PBMCs were stimulated with 1 µg/ml of S 864-882 for 10 days and recombinant human IL-2 (1 ng/ml, Peprotech) was added at day 4 and day 7. CD4 + T cells were sorted and analyzed by single cell TCR and RNA sequencing.

Single cell capturing and library preparation were performed using following The raw reads were processed by Cell Ranger 3.1.0 (10x Genomics). Gene expression-based clustering was performed using the Seurat R package (v3.1)(Hafemeister and Satija, 2019). Briefly, cells with a mitochondrial content above 10%, cells with less than 200 or more than 4,000 genes detected were considered outliers (dying cells, empty droplets and doublets, respectively) and filtered out. The

Seurat SCTransform function was used for normalization, and data was integrated without performing batch-effect correction as all samples were processed simultaneously. Hashtag oligo demultiplexing was performed on CLR-normalized hashtag UMI counts, and clonotypes were matched to the gene expression data through their droplet barcodes, using Python scripts. Only cells assigned a single hashtag and a beta-chain clonotype were retained for downstream analyses.

1-3 × 10 5 PBMCs were lysed in QIAzol (Qiagen). Full-length cDNA was then synthesized using the SMARTer technology (Takara Bio), and the variable region of TCRα and β genes were amplified using TRAC/TRBC-specific primers. After sequencing of the variable region amplicons, each pair of reads was assigned a clonotype (defined as TR(A/B)V and TR(A/B)J gene, and the complementarity-determining region 3) using the MiXCR software (Bolotin et al., 2015) . For each α/β clonotype, expansion was defined as the fraction of reads for that clone divided by the total number of reads for the α/β chain, respectively, and fractions were converted to log10 for plotting and statistical analyses. 1mM Sodium Pyruvate (Gibco), 10 ng/ml of human GM-CSF (Peprotech) and IL-4 (Peprotech) for 6 days.

TCRα and β chain cDNA sequences were synthesized and cloned into retroviral vectors pMX-IRES-rat CD2 and pMX-IRES-human CD8, respectively. Two vectors containing paired TCRα and β chains were transfected together into Phoenix packaging cells using PEI MAX (Polysciences). Supernatant containing retroviruses was used for infection into mouse T cell hybridoma with an NFAT-GFP reporter gene (Matsumoto et al., 2021) to reconstitute TCRαβ pairs. TCRβ mutants were constructed by site-directed mutagenesis. For antigen stimulation, TCR-reconstituted cells were co-cultured with stimulants in the presence of immortalized autologous B cells unless indicated otherwise. After 20 hours, T cell activation was assessed by GFP or CD69 expression.

For the preparation of pooled peptide matrix, 15-mer peptides with 11 amino acids overlap that cover the full length of S protein of SARS-CoV-2 were individually synthesized (GenScript). Peptides were dissolved in DMSO at 12 mg each peptide/ml and 8-12 peptides were mixed to create 75 different semi-pools so that the responsible epitopes can be determined from the reactivities of horizontal and vertical pools. Pooled peptides were diluted 10 times with water, followed by adding 1 µl of the solution into each corresponding well. S peptide pools and S 864-882 peptide were also loaded as controls. S peptide pools of common cold HCoVs were loaded to assess cross-reactivities. For reporter cell assay, 100 µl of media containing T cells and APCs were added to the wells so that T cells are stimulated with each peptide at 1 µg/ml.

After 20 hours, GFP reporter induction was assessed in T cell-gated population using

AttuneNxT flow cytometer (Thermo Fisher Scientific).

For the clonotypes detected in more than one donor from our sample pool, reporter cells in-house bulk TCR sequencing. TCR occurrence in a dataset was defined as the fraction of patients whose repertoire contained the given TCR, regardless of its expansion.

Expression constructs encoding the extracellular domains of TCRα-017 (Q1-D207 in mature protein) and TCRβ-017 (G1-G241) subunits were incorporated into pCold vector including 6 × His-tag and a tobacco etch virus protease cleavage site. For crystallization, the point mutations (T159C in α and S166C/C184A in β) were introduced to form artificial disulfide bond as described previously (Boulter et al., 2003) .

The plasmids were transformed into E. coli BL21 competent cells Champion21 and κ Isotype Control (eB149/10H5) was purchased from eBioscience.

Statistical analysis was performed with t-test using SciPy and p-values were indicated in Figure 3A and 4D.

Recombinant Hashtagged cells from two patients were pooled and analyzed with cell sorter.

Antigen-responded (CD69 + or CD137 + or CD154 + ) CD3 + T cells were sorted and immediately subjected to single-cell TCR and RNA sequencing. Each collection day after diagnosis is shown after the sample ID. Clonotypes excluding those with Treg characteristics were assembled with in-house bulk TCR-seq data as well as those in cohort databases. Clonotypes that satisfied following two criteria are shown: 1) expanded during stimulation based on single cell sequencing (> 0.1% of total CD4 + T cells) and 2) detected in cohort databases. 

TRAV12-1 TRAJ12 TRBV11-2 TRBJ2-7 1 2 3 4 5 6 7 8 9 10 11 12 A 0 . 9 3 0 . 9 5 0 . 9 7 0 . 9 1 0 . 9 5 0 . 9 3 0 . 7 9 1 . 0 3 0 . 9 6 1 . 0 5 0 . 7 9 0 . 8 6 Figure S1 Sorting CD69 + or CD137 + or CD154 + cells

PBMCs from healthy donors and convalescent COVID-19 patients were stimulated with SARS-CoV-2-derived antigens as indicated for 20 hours followed by staining with eight different hashtag antibodies (#1-8), anti-CD3 and indicated activation marker antibodies. Hashtagged cells from two patients were pooled and analyzed with cell sorter. Antigenresponded (CD69 + or CD137 + or CD154 + ) CD3 + T cells were sorted and immediately subjected to single-cell TCR and RNA sequencing. Each collection day after diagnosis was shown after sample ID. HCoV-OC43

HCoV-HKU1

Plate#1 (S1-S381)

Plate#4 (S1153-S1257) Plate#3 (S769-S1149) DMSO 769 773 777 781 785 789 793 797 801 805 809 813 817 821 825 829 833 837 841 845 849 853 857 861 865 869 873 877 881 885 889 893 897 901 905 909 913 917 921 925 929 933 937 941 945 949 953 957 961 965 969 973 977 981 985 989 993 997 1001 1005 1009 1013 1017 1021 1025 1029 1033 1037 1041 1045 1049 1053 1057 1061 1065 1069 1073 1077 1081 1085 1089 1093 1097 1101 1105 1109 1113 1117 1121 1125 1129 1133 1137 1141 1145 Table S6 . S864-882-reacted public Tfh clonotypes, related to Figure 6 . Clonotypes excluding those with Treg characteristics were assembled with in-house bulk TCR-seq data as well as those in cohort databases. Clonotypes that satisfied following two criteria are shown: 1) expanded during stimulation based on single cell sequencing (> 0.1% of total CD4 + T cells) and 2) detected in cohort databases. 

Towards automated crystallographic structure refinement with phenix.refine

Introduction of two prolines and removal of the polybasic cleavage site leads to optimal efficacy of a recombinant spike based SARS-CoV-2 vaccine in the mouse model

Ectopic colonization of oral bacteria in the intestine drives TH1 cell induction and inflammation

Low-Avidity CD4+ T Cell Responses to SARS-CoV-2 in Unexposed Individuals and Humans with Severe COVID-19

Polymorphism, recombination, and linkage disequilibrium within the HLA class II region

MiXCR: Software for comprehensive adaptive immunity profiling

Stable, soluble T-cell receptor molecules for crystallization and therapeutics

SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19